MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Topic
HER2/EGFR in Cancer Research
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

1,303 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
1,303 works in the cohort · of 4,299,418page 11 of 27

Labels cover 3 of 1,303 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 1,303 of 1,303 works in this cohort. Predictions are machine_predicted_unvalidated teacher distillation outputs. Candidate is the union; consensus is the intersection.

affno abstractunlabeled
Pharmacologic insights into the future of trastuzumab
Brian Leyland‐Jones, Andrew Arnold, Karen Gelmon, S. Verma, Jean-Pierre Ayoub, Andrew D. Seidman +3 more
2001· review· en· Annals of Oncology· Medicine
distilled prediction:candidate · insufficient_payloadconsensus · none
22
citations
affunlabeled
Heritable Variation of<i>ERBB2</i>and Breast Cancer Risk
Joan P. Breyer, Melinda E. Sanders, David Airey, Qiuyin Cai, Brian L. Yaspan, Peggy A. Schuyler +9 more
2009· article· en· Cancer Epidemiology Biomarkers & Prevention· Medicine
distilled prediction:candidate · noneconsensus · none
22
citations
affunlabeled
TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2− breast cancer
Heather L. McArthur, Sara M. Tolaney, Rebecca Dent, Peter Schmid, Jamil Asselah, Qiang Liu +9 more
2025· article· en· Therapeutic Advances in Medical Oncology· Medicine
distilled prediction:candidate · metaepi_narrow+insufficient_payloadconsensus · none
21
citations
affno abstractunlabeled
HER-2 positive gastric cancer: Current targeted treatments
Rama Rao Malla, Haasita Reddy Nellipudi, Mundla Srilatha, Ganji Purnachandra Nagaraju
2024· review· en· International Journal of Biological Macromolecules· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
21
citations
affunlabeled
Open-label, randomized, multicenter, phase 3 study evaluating trastuzumab deruxtecan (T-DXd) as first-line treatment in patients with unresectable, locally advanced, or metastatic non–small cell lung cancer (NSCLC) harboring HER2 exon 19 or 20 mutations (DESTINY-Lung04).
Bob T. Li, Myung‐Ju Ahn, Kōichi Goto, Julien Mazieres, Sukhmani K. Padda, William Nassib William +5 more
2022· article· en· Journal of Clinical Oncology· Medicine
distilled prediction:candidate · metaresearch+metaepi_narrow+insufficient_payloadconsensus · none
21
citations
affno abstractunlabeled
LBA21 First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase III TROPION-Breast02 trial
R. Dent, Zhi-Ming Shao, P. Schmid, J. Cortés, David W. Cescon, Shigehira Saji +12 more
2025· article· en· Annals of Oncology· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
21
citations
aboutno affunlabeled
Abstract PD5-04: NSABP FB-7: A phase II randomized trial evaluating neoadjuvant therapy with weekly paclitaxel (P) plus neratinib (N) or trastuzumab (T) or neratinib and trastuzumab (N+T) followed by doxorubicin and cyclophosphamide (AC) with postoperative T in women with locally advanced HER2-positive breast cancer
SA Jacobs, A. Robidoux, J. A. Garcia, Jame Abraham, Nicla La Verde, JM Orcutt +9 more
2016· article· en· Cancer Research· Medicine
distilled prediction:candidate · metaepi_narrow+insufficient_payloadconsensus · none
20
citations

How this was built: Screen · Findings · About